Journal
ENDOCRINE PRACTICE
Volume 22, Issue 1, Pages 84-102Publisher
ELSEVIER INC
DOI: 10.4158/EP151126.CS
Keywords
-
Categories
Funding
- Novo Nordisk
- AstraZeneca
- Boehringer Ingelheim
- Freedom-Meditech
- Asahi
- Eli Lilly
- Abbott
- Endo Barrier
- Gilead
- Merck
- Weight Watchers
- Sanofi
- Eisai
- Pfizer
- Glaxo
- Medtronic
- Amgen
- BI
- Grifols
- Himni
- Intarcia
- Lexicon
- Takeda
- Hitachi
- Viacyte
- Novartis
- Dexcom
- Amarin
- Lilly
- Sanofi-Regeneron
- Bristol-Myers Squibb
- MannKind
- Novo
- Nordisk
- Orexigen
- Regeneron
- Asahi Kasei
- Lexicom
Ask authors/readers for more resources
This algorithm for the comprehensive management of persons with type 2 diabetes (T2D) was developed to provide clinicians with a practical guide that considers the whole patient, their spectrum of risks and complications, and evidence-based approaches to treatment. It is now clear that the progressive pancreatic beta-cell defect that drives the deterioration of metabolic control over time begins early and may be present before the diagnosis of diabetes (1). In addition to advocating glycemic control to reduce microvascular complications, this document highlights obesity and prediabetes as underlying risk factors for the development of T2D and associated macrovascular complications. In addition, the algorithm provides recommendations for blood pressure (BP) and lipid control, the two most important risk factors for cardiovascular disease (CVD). Since originally drafted in 2013, the algorithm has been updated as new therapies, management approaches, and important clinical data have emerged. The 2016 edition includes a new section on lifestyle therapy as well as discussion of all classes of obesity, antihyperglycemic, lipid-lowering, and antihypertensive medications approved by the U.S. Food and Drug Administration (FDA) through December 2015. This algorithm supplements the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) 2015 Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan (2) and is organized into discrete sections that address the following topics: the founding principles of the algorithm, lifestyle therapy, obesity, prediabetes, glucose control with noninsulin antihyperglycemic agents and insulin, management of hypertension, and management of dyslipidemia. In the accompanying algorithm, a chart summarizing the attributes of each antihyperglycemic class and the principles of the algorithm appear at the end.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available